Systemic amyloidosis represents a class of disorders in which misfolded proteins are secreted by effector organs 30 and deposited as proteotoxic aggregates at downstream target tissues. Despite being well-described clinically, 31 the contribution of effector organs such as the liver to the pathogenesis of these diseases is poorly understood. 32
INTRODUCTION 47
Traditionally, the livers of ATTR amyloidosis patients have been thought to be unaffected throughout 75 disease pathogenesis, as toxicity occurs at downstream target organs such as the heart and peripheral nerves 76 (1) (2) (3) (4) (5) (6) (7) (8) (9) . Despite this however, recent studies suggest the capacity for the liver to contribute to the deposition of 77 amyloidogenic proteins at distal target tissues. In line with this, recipients of domino liver transplantations (DLTs), 78
where an individual in end-stage liver failure receives a liver from an ATTR amyloidosis patient, show accelerated 79 TTR amyloid disease pathogenesis, wherein TTR fibrils accumulate on target organs in fewer than 10 years (21-80 26). Furthermore, in vivo mouse experiments have shown that the deposition of TTR on the hearts of old mice 81 correlates with altered expression of numerous genes in the liver associated with the regulation of hepatic 82 proteostasis (27). These results implicate the liver in the pathogenesis of systemic amyloid diseases such as 83 ATTR amyloidosis. Despite these observations however, the molecular and cellular changes in the liver that 84 contribute to the toxic aggregation of misfolded TTR in distal tissues remains unclear. 85
Interestingly, significant evidence highlights an important role for endoplasmic reticulum (ER) 86 proteostasis in regulating the secretion and subsequent aggregation of amyloidogenic proteins such as TTR (28-87 32). The capacity of the ER proteostasis environment to secrete destabilized, aggregation-prone TTR variants 88 has been directly implicated in the onset and pathogenesis of ATTR amyloidosis-related disorders. Furthermore, 89 activation of adaptive IRE1/XBP1s or ATF6 arms of the unfolded protein response (UPR) -the predominant 90 signaling pathway responsible for regulating ER proteostasis -have been shown to reduce the secretion and 91 subsequent aggregation of structurally diverse amyloidogenic proteins (including TTR) (29, 31) . Despite this, the 92 physiological importance of ER proteostasis and the UPR in ATTR amyloidosis remains poorly defined. 93
Here, we utilize our laboratory's previously described patient-specific iPSC-based model of ATTR 94 amyloidosis to investigate the contribution of proteostasis and hepatic disease modifying factors to the distal 95 toxicity observed in patients with the disease. By utilizing gene editing in combination with single cell RNA 96 sequencing (scRNAseq), we define distinct transcriptional profiles in syngeneic corrected and uncorrected ATTR 97 amyloidosis iPSC-derived HLCs that correlate with expression of a destabilized, amyloidogenic TTR variant. 98
Through these efforts, we show that expression of the most proteotoxic, destabilized, disease-associated TTR 99 mutant in HLCs increases expression of genes and pathways inversely implicated in the toxic extracellular 00 aggregation of TTR, including transferrin and UPR target genes. To assess the consequence of functional 01 activation of adaptive UPR signaling within hepatic cells expressing mutant TTR, we generated an ATF6-inducible patient-specific iPSC line. We further utilize this tool to demonstrate that exogenous ATF6 activation 03 preferentially reduces the secretion of mutant, amyloidogenic TTR relative to the wild-type protein. 04
Herein, we demonstrate that hepatic expression of amyloidogenic TTR results in differential expression 05 of proteostasis factors known to protect the extracellular space from toxic protein aggregation. 06 07 RESULTS 08 TTR is a top differentially expressed gene throughout human hepatic specification. 09
Recent work from our group demonstrated the emergence of a stage-dependent disease signature of hepatic-10 specified pluripotent stem cells (PSCs) (33). In these experiments, microarray analyses were performed on cells 11 isolated at days 0, 5, and 24 of hepatic differentiation. Post-hoc analysis of this data revealed that TTR was the 12 second most differentially expressed gene comparing differentiated HLCs to PSCs (Fig. 1A) . To confirm this, 13 qRT-PCR was performed on RNA isolated from day 24 HLCs, demonstrating significant upregulation of TTR as 14 compared to undifferentiated iPSCs (Fig. 1B) . These data demonstrate that TTR is a robust marker of hepatic 15 specification and can be used to normalize stem cell-derived hepatic differentiations. 16 17 Gene editing of ATTR amyloidosis iPSCs eliminates secretion of mutant TTR L55P and decreases target cell 18 toxicity. 19
As noted above, TTR is one of the most differentially expressed genes in HLC differentiations, suggesting it 20 might serve as an excellent candidate locus to target and generate a hepatic specification reporter iPSC line. To 21 this end, we employed TALEN-mediated gene editing to manipulate an iPSC line derived from a patient with the 22 Leu55 →Pro (TTR L55P ) mutation, the most proteotoxic disease-causing variant (34, 35) . In order to implement a 23 broadly applicable gene correction strategy, we targeted the ATG start site of the endogenous, mutant TTR 24 allele, introducing a normal TTR coding sequence, followed by a 2A self-cleaving peptide and eGFP coding 25 sequence (Fig. 1C) . Inclusion of a 2A peptide allows for transcription of a single mRNA that ultimately results in 26 two independent TTR and GFP proteins via a post-translational cleavage event. As a result of this targeting 27 methodology, transcription and translation of mutant TTR is abrogated via introduction of an artificial STOP 28 codon and polyA sequence, and replaced with a normal TTR coding sequence (Fig. 1C) . Importantly, this 29 universal gene correction strategy provides a singular technique for correcting all known TTR genetic lesions while simultaneously obviating concerns regarding haploinsufficiency via replacement of the endogenous mutant 31 TTR allele with a wild-type copy. (Additional information regarding generation and characterization of corrected 32 iPSCs can be found in Supplemental Fig. 1 
.) 33
Using this TTR reporter line, we then measured the kinetics of GFP expression throughout HLC 34 differentiation by flow cytometry. In doing so, we found that expression of GFP peaked at approximately day 16 35 of a 24-day specification protocol (Fig. 1D) . By day 24 of the differentiation, HLCs exhibited cobblestone-like 36 morphology, and the majority of cells expressed GFP (Fig. 1E) . To further validate this reporter line and ensure 37 that GFP expression correlated with the expression of TTR as well as other hepatic-specification markers, day 38 16 GFP + HLCs were sorted and assayed via qRT-PCR. GFP + cells expressed high levels of TTR, as well as 39 other hepatic specification markers such as AAT and ALB (Fig. 1F ), suggesting that our corrected reporter cell 40 line labels maturing hepatic-lineage cells during specification. 41 We further examined the ability of this strategy to eliminate the production of destabilized, disease-42 causing TTR, as well as alleviate downstream toxicity (outlined in Fig. 2A) . Normal, corrected, and non-43 targeted, heterozygous TTR L55P iPSCs were differentiated into HLCs. Conditioned supernatant from each line 44 was harvested after culturing cells for 72 hours in hepatic specification media beginning on day 16 of the 45 differentiation. We used liquid chromatography (LC)/mass spectrometry (MS) to show that TTR immunopurified 46 from normal hepatic supernatants contained TTR WT , but not TTR L55P , while supernatants collected from patient 47 iPSC-derived HLCs contained both TTR WT and TTR L55P (Fig. 2B) . Supernatant from corrected iPSC-derived 48
HLCs revealed complete elimination of TTR L55P , while levels of TTR WT remained unperturbed (Fig. 2B) . 49 toxicity. In these assays, SH-SY5Y cells dosed with mutant hepatic supernatant displayed an increase in PI + 59 cells compared to those dosed with normal supernatant (Fig. 2C ). Cells dosed with corrected supernatant, 60 however, exhibited a decrease in toxicity comparable to levels observed in the normal control sample (Fig. 2C) . 61
These results suggest that the proposed gene correction strategy ameliorates TTR-mediated toxicity via 62 reductions in the hepatic secretion of destabilized TTR. 63
64
Single cell RNA sequencing reveals a novel hepatic gene signature associated with the production of 65 destabilized TTR L55P . 66
Historically, it has been thought that the livers of patients with ATTR amyloidosis are unaffected during disease 67 pathogenesis (1-9). Recent work however, calling into question the use of donor organs from ATTR amyloidosis 68 patients for DLT procedures challenges this notion (21-26). Furthermore, evidence highlights a significant 69 potential role for the liver in regulating the extracellular aggregation and distal deposition of TTR implicated in 70 ATTR amyloidosis disease pathogenesis (27). Collectively, these results indicate that genetic or aging-related 71 perturbations to the liver could influence the toxic extracellular aggregation and deposition of TTR aggregates 72 on peripheral target tissues. 73
In order to define specific hepatic proteins and pathways associated with the production of destabilized, 74 amyloidogenic TTR variants, we coupled our TTR reporter system with single cell RNA sequencing (scRNAseq) 75 to compare mRNA expression profiles in syngeneic iPSC-derived HLCs with or without the TTR L55P mutation. In 76 addition to our corrected TTR reporter iPSC line, we also constructed a reporter cell line where our TTR-GFP 77 donor construct was targeted to the wild-type TTR allele in the same TTR L55P parental iPSC line. As a result, we 78 created two syngeneic, TTR-promoter driven hepatic-specification reporter iPSC lines, where the only difference 79 is the presence or absence of the disease causing TTR L55P mutation (henceforth referred to as uncorrected and 80 corrected cells, respectively). To compare HLCs +/-TTR L55P , uncorrected and corrected reporter iPSCs were 81 subjected to our hepatic specification protocol until TTR expression had plateaued (at day 16 of the 82 differentiation) (Fig. 1D) . To control for the inherent heterogeneity of iPSC differentiations, GFP + cells were 83 purified by FACS to select for cells undergoing hepatic-specification (i.e. at similar stages in their developmental 84 trajectories). Transcriptomic profiling was subsequently performed at single cell resolution via the Fluidigm C1 Day 16 uncorrected and corrected HLCs formed clear and distinct groups by supervised principal 87 component analysis (PCA), with 92 genes differentially expressed between the two groups ( Fig. 3B-3D , 88
Supplemental Data File 1) (significance determined via one-way ANOVA, FDR cutoff <0.05). These analyses 89 identified increased expression of distinct genes and pathways previously shown to influence extracellular 90 aggregation of destabilized TTRs in uncorrected but not corrected HLCs (vide infra) (28-32). 91
92
Transferrin expression is significantly increased in uncorrected HLCs and may represent a novel chaperone for 93 destabilized TTR. 94
The top differentially expressed gene in uncorrected HLCs is the iron transporter, transferrin (TF) ( Fig. 3C, 3D) . 95
Although TF is a known hepatic lineage marker, no other hepatic markers (including: TTR, ALB, AFP, HNF4A, 96 FOXA1, GATA4, SERPINA1, FGB, DUOX2, A2M, TGM2, HAVCR1, GATA6) are differentially expressed 97 between corrected and uncorrected HLCs, suggesting that the differential expression of TF is not simply due to 98 the differentiation status of individual lines ( Fig. 3D and Supplemental Fig. 2) . 99
Interestingly, previous studies have demonstrated the ability of TF to act as a chaperone in the context 00 of other amyloid disorders such as Alzheimer's Disease (AD) as well as to physically interact with TTR fibrils in 01 vivo (39). As a result, we sought to assess the capacity for TF to act as a novel chaperone for misfolding TTR 02 and in turn prevent TTR fibril formation. To this end, we performed an in vitro fibril formation assay whereby the 03 formation of congophilic fibrils from bacterial-derived, recombinant TTR L55P was assessed with or without the 04 addition of TF ( Fig. 4A) . In doing so, iron-free TF (apo-transferrin) at physiologically-relevant concentrations (30 05 µM) reduced the amount of congophilic species formed by approximately 60% (Fig. 4B ). This suggests that the 06 increased expression of TF in HLCs containing mutant TTR L55P could represent a mechanism to suppress 07 aggregation-associated toxicity. 08 09 Uncorrected HLCs show increased activation of protective UPR-associated signaling pathways. 10 Apart from TF, our scRNAseq analysis also identified increased expression of multiple UPR-regulated ER 11 proteostasis factors (e.g., HYOU1 and EDEM2; Fig. 3C, 3D ) in iPSC-derived HLCs expressing TTR L55P . These 12 genes play important roles in regulating proteostasis within the ER. Thus, the increased expression of these ER proteostasis factors suggests that the presence of the destabilized TTR L55P protein challenges the ER 14 proteostasis environment and in turn activates the UPR. 15
Interestingly, ER stress and UPR activation can influence the toxic extracellular aggregation of 16 amyloidogenic TTR mutants implicated in ATTR amyloidosis disease pathogenesis (28-32). Chemical toxins that 17 induce severe, unresolvable ER stress in mammalian cells decrease the population of amyloidogenic TTR 18 secreted as the native TTR tetramer and instead increase TTR secretion in non-native conformations that rapidly 19 aggregate into soluble oligomers implicated in ATTR amyloidosis disease pathogenesis (28, 40) . In contrast, 20 enhancing ER proteostasis through the stress-independent activation of the adaptive UPR-associated 21 transcription factor ATF6, selectively reduces the secretion and subsequent aggregation of destabilized, 22 amyloidogenic TTR variants (29-32). This suggests that activation of adaptive UPR signaling pathways 23 independent of severe ER stress is a protective mechanism to suppress the secretion and toxic aggregation of 24 destabilized, amyloidogenic TTR mutants. 25
In order to better define the impact of TTR L55P expression on ER stress and UPR activation, we used 26 gene set enrichment analysis (GSEA) to define the extent of UPR pathway activation in our uncorrected iPSC-27 derived hepatic lineages. Notably, this analysis revealed modest activation of the adaptive IRE1/XBP1s and 28 ATF6 UPR transcriptional signaling pathways, with no significant activation of the pro-apoptotic PERK UPR 29 pathway ( Fig. 4C) . We confirmed IRE1/XBP1s activation in two independent patient-specific iPSC-derived HLCs 30 by monitoring IRE1-dependent XBP1 splicing ( Fig. 4D-F) . As a positive control, cells were dosed with global 31 UPR activator thapsigargin. These results show that expression of destabilized, amyloidogenic TTR L55P promotes 32 adaptive remodeling of ER proteostasis through the IRE1/XBP1s and ATF6 UPR signaling pathways. 33
34
Hepatic activation of ATF6 signaling selectively reduces secretion of destabilized TTR L55P . 35
We next determined the consequence of functional activation of adaptive UPR-associated signaling pathways 36 in ATTR amyloidosis patient-specific iPSC-derived hepatic cells expressing mutant, destabilized TTR. To 37 accomplish this, we introduced an ATF6-inducible donor construct into our previously described heterozygous 38 TTR L55P patient-specific iPSC line. In these cells, the coding sequence for the active N-terminal bZIP transcription 39 factor domain of ATF6 is fused to a destabilized dihydrofolate reductase (DHFR) tag as previously described 40 (32). In the absence of chemical chaperone trimethoprim (TMP), the DHFR.ATF6 protein product is targeted for degradation via the ubiquitin proteasome system ( Fig. 5A) . Upon administration of TMP, the DHFR domain is 42 stabilized, allowing dosable, stress-independent activation of ATF6 transcriptional activity ( Fig. 5A) . ATF6-43 inducible iPSCs were differentiated into HLCs and subsequently dosed with TMP, beginning on day 15 of hepatic 44 specification. Administration of TMP induced selective expression of the ATF6 target genes HSPA5 and 45 HERPUD1, but not an IRE1/XBP1s target gene (e.g., ERDJ4) or PERK target gene (e.g., GADD34) ( Fig. 5C , 46 5D), confirming selective TMP-dependent ATF6 activation in these HLCs. We then collected conditioned media 47 for 72 hours on patient iPSC-derived HLCs dosed with or without TMP and monitored the relative populations of 48 TTR WT and TTR L55P by mass spectrometry. We initially showed that the relative recovery of TTR L55P from IPs of 49 media prepared on HLCs treated with TMP was reduced relative to TTR WT , suggesting reduced secretion of this 50 destabilized TTR variant induced by stress-independent ATF6 activation (supplemental Fig. 3A, 3B ). To better 51 quantify this reduction, we performed Tandem Mass Tag (TMT) / LC-MS/MS quantitative proteomics to directly 52 monitor the relative amounts of peptides comprising TTR WT or TTR L55P in these conditioned media ( Fig. 5E) . 53
Using this quantitative approach, we show that TMP-dependent ATF6 activation preferentially reduces levels of 54 destabilized TTR L55P 25% relative to TTR WT in HLC conditioned media. This demonstrates that stress-55 independent ATF6 activation selectively reduces secretion of destabilized, amyloidogenic TTR L55P in patient 56 iPSC-derived HLCs. We moreover found that branch-specific activation of ATF6 signaling protects iPSC-derived 57
HLCs from morphological defects resulting from prolonged exposure to severe ER stress via addition of 58 thapsigargin (supplemental Fig. 4A, 4B) . 59
60

DISCUSSION 61
Herein, we describe the utilization of gene editing technology in ATTR amyloidosis patient-specific iPSCs in 62 order to uncover a novel human hepatic gene signature resulting from the expression of destabilized, misfolding-63 prone TTR. Historically, the livers of patients with ATTR amyloidosis were thought to be unaffected in disease 64 pathogenesis (1) (2) (3) (4) (5) (6) . This is best highlighted through the employment of DLTs, wherein the livers of patients with 65 ATTR amyloidosis are removed and given to individuals in end-stage liver failure. Despite routine use of these 66 transplants, recent clinical data demonstrates that non-ATTR amyloidosis DLT recipients not only go on to 67 develop amyloidogenic TTR fibrils (and disease), but they do so at a median time of only 7.5 years post-68 transplant (21-26). While these clinical observations suggest a role for the liver in contributing to pathogenesis of ATTR amyloidosis and potentially other systemic amyloid diseases, the cellular and molecular mechanisms 70 for this phenomenon remain unknown. 71
Through the use of gene editing and scRNAseq, we defined distinct transcriptional profiles for hepatic 72 cells expressing destabilized TTR L55P . We hypothesized that hepatic production of destabilized TTRs results in 73 the upregulation of stress-responsive proteostasis factors that regulate the secretion and subsequent 74 aggregation of destabilized TTR variants such as TTR L55P . Our scRNAseq experiment revealed that uncorrected 75 hepatic cells exhibited differential expression of 92 genes compared to syngeneic hepatic cells where the only 76 difference is the absence of expression of the mutant TTR. In line with our rationale, we identified many instances 77 in which mutant hepatic cells upregulated expression of well-documented ER stress-associated proteostasis 78 factors involved in regulating protein secretion (e.g., HYOU1, EDEM2). 79
Interestingly, TF was found to be the most upregulated gene in uncorrected, TTR L55P -expressing hepatic 80 cells. Despite limited prior evidence for TF as a chaperone for misfolded TTRs, recent work implicates its 81 chaperone capacity in other amyloid disorders such as Alzheimer's Disease (AD), noting increased protein-level 82 expression in the prefrontal cortices of AD patients compared to elderly, non-diseased individuals (41) . Moreover, 83 recent work demonstrated the ability of TF to physically interact with and prevent the self-assembly and toxicity 84 of amyloid ß peptide (Aß) oligomers, the amyloidogenic protein species in AD (42, 43). At the same time, recent 85 in vivo data have demonstrated physical interactions between TF and TTR amyloid fibrils (39). Through the use 86 of congophilic fibril formation assays, we demonstrated that iron-free TF at physiologically relevant levels, 87 decreased in vitro TTR L55P fibril formation by approximately 60%, implicating TF as a novel chaperone for hepatic 88
TTRs. These observations, together with our scRNAseq and biochemical data, suggest the possibility that TF 89 plays a similar protective role in ATTR amyloidosis. In this model, hepatic cells producing mutant TTR may 90 express higher levels of TF to prevent toxicity and/or fibril formation. 91
In addition to the differential expression of known and novel chaperone genes, we noted activation of the 92 adaptive arms of the UPR (ATF6 and IRE1/XBP1s) in hepatic cells expressing mutant TTR. Together, these 93 data indicate that the expression of TTR L55P in iPSC-derived HLCs does not induce severe ER stress, but 94 suggests that the activation of adaptive IRE1/XBP1s and ATF6 signaling observed in these cells reflects a 95 protective mechanism to suppress secretion and subsequent aggregation of the destabilized TTR L55P protein.
TTR L55P levels were approximately 30% that of TTR WT (Fig. 2B) . This result mirrors the lower levels of 98 destabilized TTR mutants (as compared to wild-type TTR) observed in conditioned media prepared on hepatic 99 cells expressing both variants (18-20, 28-32). 00
Our scRNAseq experiments demonstrate dynamic activation of proteostasis transcriptional networks 01 consisting of upregulation of chaperones as well as functional activation of adaptive UPR-associated signaling 02 pathways in mutant HLCs. Due to the gradual nature of the deposition of TTR aggregates and fibrils, with disease 03 manifesting clinically around the 5 th or 6 th decade of life, ATTR amyloidosis is widely considered an aging-related 04 disorder. It is well-understood that proteostasis factors and the ability to cope with the production of misfolded 05 proteins decreases with age, while similarly, iron has been shown to increase in a number of organs throughout 06 aging (41) (42) (43) (44) (45) (46) . Interestingly, since UPR signaling declines during normal aging (47-50), the presence of adaptive 07 UPR signaling in the above-mentioned HLCs could reflect protective biologic pathways whose activity also 08 decline during the aging process. Aging-dependent reductions in adaptive UPR signaling could exacerbate 09 TTR L55P -associated ER stress and increase secretion of TTR in non-native conformations that facilitate toxic 10 extracellular aggregation. Thus, monitoring changes in hepatic UPR activation and/or conformational stability of 11 circulating TTR tetramers could reflect a potential biomarker to monitor progression of TTR amyloid disease 12 pathogenesis (51) -a notoriously difficult disorder to diagnose. 13
Together, these results indicate that the expression of a destabilized, aggregation-prone protein 14 upregulates proteostasis factors as well as functionally activates adaptive UPR-associated signaling pathways 15 in ATTR amyloidosis patient-specific iPSC-derived hepatic cells. Moreover, we demonstrated that inducible 16 activation of ATF6 signaling in these cells resulted in a ~25% reduction of destabilized TTR L55P while wild-type 17 levels appeared unaffected. Despite a relatively modest decrease, this reduction could represent a shift toward 18 stability where properly folded, mutant TTRs form stabilized heterotetramers with wild-type TTRs (52). 19
Conventional therapeutics for many systemic amyloid diseases involve decreasing circulating levels of 20 the amyloidogenic protein. In the case of ATTR amyloidosis, for example, liver transplantation relies upon 21 eliminating circulating levels of mutant TTR. Similarly, emerging RNAi-based therapeutics are being developed 22 to target and eliminate wild-type and mutant TTR transcripts within liver tissue (53-56). Activating ATF6 signaling 23 in ATTR amyloidosis hepatic cells could result in a therapeutic decrease in the secretion of misfolding-prone 24
TTRs from the liver and thus a decrease in extracellular deposition of proteotoxic aggregates as distal target tissues. Recent studies have demonstrated that stress-independent, selective activation of ATF6 signaling is 26 achievable via addition of small molecules (29, 32, 57). At the same time, upregulation of ATF6 signaling is 27 relatively tolerated in humans with hyperactivating mutations (38, 39, 57) . Future work will aim to further the 28 development of small molecule-based ATF6-modulating compounds for the treatment of systemic amyloid 29 diseases such as ATTR amyloidosis. 30
Results from these experiments challenge the long-held notion that the livers of patients with ATTR 31 amyloidosis are unaffected by the disease and do not contribute to pathogenesis. Through the use of our novel 32 iPSC-based model, our work demonstrates that expression of amyloidogenic TTR results in transcriptional and 33 functional changes in ATTR amyloidosis hepatic cells. Moreover, these data suggest that the liver employs 34 protective mechanisms via adaptive UPR-associated signaling pathways in order to cope with the production of 35 misfolding-prone TTRs. Furthermore, this work demonstrates that modulation of UPR-associated ATF6 signaling 36 results in a selective decrease in the secretion of misfolded proteins in patient-specific iPSC-derived hepatic 37 cells, and could potentially represent a broadly applicable therapeutic strategy for complex and diverse systemic 38 amyloid disorders. Sequencing was performed on a Nextseq 500 using a high-output kit. This resulted in a total of 430 million paired-07 end, 75 bp reads. Reads were aligned to the human genome (GRCh38) and quantified using the STAR aligner away from median total reads, mitochondrial counts), in addition to removing a subpopulation determined 10 through k-means clustering with high mitochondrial expression and low numbers of genes expressed. This 11 resulted in 120 cells available for analysis, with a mean of 482,205 aligned reads/cell. Size factors were 12 computed via the Scran Bioconductor package, which uses pool-based scaling factors and deconvolution, 13 followed by log-transformation normalization using the Scater package (64). A one-way ANOVA was used to 14 determine significantly (FDR <0.05) differentially expressed genes between corrected and uncorrected cells. were considered as static modifications. Data was searched with 50 ppm precursor ion tolerance and 600 ppm 86 fragment ion tolerance. Identified proteins were filtered to 10 ppm precursor ion tolerance using DTASelect (72) 87 and utilizing a target-decoy database search strategy to control the false discovery rate to 1% at the protein level 88 (73). Quantitative analysis was done with Census (74) filtering reporter ions with 20 ppm mass tolerance and 0.6 89 isobaric purity filter. TTR WT or TTR L55P were initially analyzed for each biological replicate. Peptides showing a m/z signal less than 92 10,000 were excluded from the analysis. A TMP ratio for each identified peptide was quantified using the 93 following equation: TMP ratio = peptide signal in +TMP channel replicate = n / peptide signal -TMP channel 94 replicate = n. The TMP ratio for individual peptides was then averaged across all peptides observed for each 95 individual biological replicate to generate the plots shown in Supplemental Fig. 3 . The relative impact of TMP 96 on the secretion of TTR L55P was then quantified by normalizing the average TMP ratio for the TTR L55P peptide to 97 the TMP ratio for the TTR WT peptide to generate the plot shown in Fig. 5D . 98
99
Morphological assessment of the impact of ATF6 signaling on HLCs exposed to prolonged ER stress. 00
To assess morphological differences under severe, prolonged stress, iPSC-derived HLCs were dosed with 50 01 nM thapsigargin for 5 days beginning on day 15 of the differentiation. In stressed cells with ATF6 activation, TMP 02 was simultaneously added at a concentration of 10 µM. In instances where ATF6 signaling was inhibited in the 03 presence of thapsigargin, 6 µM Ceapin-A7 (CP7) (Sigma-Aldrich, Cat. No. SML2330) was added to cells. After 04 dosing for 5 days, cell morphology was noted. To account for degradation, small molecules were supplemented 05 to media at half-concentration every other day. 06
07
STATISTICAL ANALYSIS 08
Unless otherwise stated in the text, significance was determined between experimental and control conditions 09 
